These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37793853)

  • 1. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
    Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
    Mazahreh R; Mason ML; Gosink JJ; Olson DJ; Thurman R; Hale C; Westendorf L; Pires TA; Leiske CI; Carlson M; Nguyen LT; Cochran JH; Okeley NM; Yumul R; Jin S; Stone IJ; Sahetya D; Nesterova A; Allred S; Hensley KM; Hu R; Lawrence R; Lewis TS; Sandall S
    Mol Cancer Ther; 2023 Apr; 22(4):421-434. PubMed ID: 36800443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.
    Heiser RA; Cao AT; Zeng W; Ulrich M; Younan P; Anderson ME; Trueblood ES; Jonas M; Thurman R; Law CL; Gardai SJ
    Mol Cancer Ther; 2024 Jan; 23(1):68-83. PubMed ID: 37775098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
    Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab Vedotin (SGN-35).
    Katz J; Janik JE; Younes A
    Clin Cancer Res; 2011 Oct; 17(20):6428-36. PubMed ID: 22003070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
    Toader D; Fessler SP; Collins SD; Conlon PR; Bollu R; Catcott KC; Chin CN; Dirksen A; Du B; Duvall JR; Higgins S; Kozytska MV; Bellovoda K; Faircloth C; Lee D; Li F; Qin L; Routhier C; Shaw P; Stevenson CA; Wang J; Wongthida P; Ter-Ovanesyan E; Ditty E; Bradley SP; Xu L; Yin M; Yurkovetskiy AV; Mosher R; Damelin M; Lowinger TB
    Mol Cancer Ther; 2023 Sep; 22(9):999-1012. PubMed ID: 37294948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.
    Lyon RP; Jonas M; Frantz C; Trueblood ES; Yumul R; Westendorf L; Hale CJ; Stilwell JL; Yeddula N; Snead KM; Kumar V; Patilea-Vrana GI; Klussman K; Ryan MC
    Mol Cancer Ther; 2023 Dec; 22(12):1444-1453. PubMed ID: 37619980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
    Kinneer K; Wortmann P; Cooper ZA; Dickinson NJ; Masterson L; Cailleau T; Hutchinson I; Vijayakrishnan B; McFarlane M; Ball K; Davies M; Lewis A; Huang Y; Rosenbaum AI; Yuan J; Chesebrough J; Anderton J; Monks N; Novick S; Wang J; Dimasi N; Christie RJ; Sabol D; Tosto FA; Wallez Y; Leo E; Albertella MR; Staniszewska AD; Tice DA; Howard PW; Luheshi N; Sapra P
    Clin Cancer Res; 2023 Mar; 29(6):1086-1101. PubMed ID: 36355054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
    Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
    Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
    Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
    J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
    Bakema JE; Stigter-van Walsum M; Harris JR; Ganzevles SH; Muthuswamy A; Houtkamp M; Plantinga TS; Bloemena E; Brakenhoff RH; Breij ECW; van de Ven R
    Mol Cancer Ther; 2024 Feb; 23(2):187-198. PubMed ID: 37828725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
    McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
    Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.